- active not recruitingPHASE3
A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy (MK-6482-022)
This study is comparing two treatments, belzutifan plus pembrolizumab, against pembrolizumab alone, for kidney cancer that has been removed. It aims to see if the combination treatment can prevent the cancer from returning.
United States · Australia · Brazil - active not recruitingPHASE3
A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011)
This study compares two treatments for advanced kidney cancer: a combination of belzutifan and lenvatinib, versus cabozantinib. It's for people whose cancer has grown even after previous treatment, aiming to find which option works better and is safer.
United States · Argentina · Australia - active not recruitingPHASE1, PHASE2
Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A)
This study is looking at new combinations of medicines for kidney cancer (renal cell carcinoma) that has spread or come back. We want to see how safe and effective these new treatments are. It's an early-stage study to find the best way to use these combinations.
United States · Australia · Canada - active not recruitingPHASE3
A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005)
This study compares a new drug called belzutifan with an existing drug, everolimus, for people with advanced kidney cancer. We want to see if belzutifan can stop the cancer from growing for longer and help people live longer than everolimus.
United States · Brazil · Canada - active not recruitingPHASE2
A Study of Belzutifan (MK-6482) in Participants With Advanced Renal Cell Carcinoma (MK-6482-013)
This study looks at a new drug called belzutifan for advanced kidney cancer. We want to see if a higher dose works better and is safe for people whose cancer has grown despite previous treatments.
United States · Australia · Belgium - active not recruitingPHASE3
A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)
This study is testing new combinations of medicines for advanced kidney cancer (renal cell carcinoma). Its aim is to see if these new combinations work better and are safe compared to a standard treatment, for people who haven't had treatment for their advanced cancer before.
United States · Australia · Brazil - active not recruitingPHASE1, PHASE2
Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B/KEYMAKER-U03)
This study looks at new drug combinations for advanced kidney cancer that has not responded to previous treatments. It aims to see how safe and effective these new combinations are.
United States · Australia · Canada